The type I diabetes program gets $200,000,000 for fiscal year 2026
What the document says“``(G) $200,000,000 for fiscal year 2026, to remain available until expended; and ``(H) $50,410,959 for the period beginning on October 1, 2026, and ending on December 31, 2026, to remain available until expended.''.”
Subsection (a) of section 6402 replaces subparagraphs (E) through (H) of section 330B(b)(2) of the Public Health Service Act. It sets $200,000,000 for fiscal year 2026 and $50,410,959 for the period from October 1, 2026 to December 31, 2026, each to remain available until expended, and restates the 2024 and 2025 figures.
What the document actually says“``(G) $200,000,000 for fiscal year 2026, to remain available until expended; and ``(H) $50,410,959 for the period beginning on October 1, 2026, and ending on December 31, 2026, to remain available until expended.''.”
For fiscal year 2026 the sum is $200,000,000. For the three months after, the sum is $50,410,959. Both may be held until spent.
Type I diabetes often starts in childhood. The body stops making insulin. This money backs research and care.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.